Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, successfully placed three tranches of U.S. dollar and euro-denominated senior unsecured notes (together the “senior notes”). Proceeds amounting to approximately $1.82 billion are intended to be used for acquisitions, including the acquisition of Liberty Dialysis Holdings, Inc., to refinance indebtedness and for general corporate purposes.

The coupon for the dollar-denominated senior notes in the principal amount of $800 million due 2019 will be 5.625% and the coupon for the dollar-denominated senior notes in the principal amount of $700 million due 2022 will be 5.875%. The coupon for the euro-denominated senior notes in the principal amount of €250 million due 2019 will be 5.25%. All tranches were issued at par.

Michael Brosnan, chief financial officer of the company, commented: “This is the largest placement of senior notes in the history of Fresenius Medical Care and an important step in the financing of our growth strategy. We are very pleased to have successfully completed this offering at favorable rates in an overall challenging market environment. We believe this demonstrates that investors continue to recognize our financial stability and sustainable financial strength.”

The dollar-denominated senior notes were offered by Fresenius Medical Care US Finance II, Inc. and the euro-denominated senior notes were offered by FMC Finance VIII S.A. Both issuers are wholly-owned subsidiaries of the company. The senior notes were offered through a private placement to institutional investors and will be guaranteed jointly and severally by the company and its subsidiaries, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.

The senior notes have not been registered under the Securities Act of 1933 as amended, but were offered to “qualified institutional buyers” (QIBs) in the U.S. pursuant to the exemption from registration provided by Rule 144A under the Securities Act and in exempted “offshore transactions” pursuant to Regulation S under the Securities Act. The senior notes may not be offered or sold in the U.S. unless registered under the Securities Act or pursuant to an applicable exemption from registration requirements.

Application has been made for admission of the senior notes to trading on the regulated market of the Luxembourg Stock Exchange.

***

About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,874 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 228,239 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

The information contained in this release may not be issued or distributed in or into Canada, Australia or Japan and does not constitute an offer to sell nor an invitation to subscribe for, underwrite or otherwise acquire securities in Canada, Australia or Japan.

This release does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of FMC Finance VIII S.A., or Fresenius Medical Care US Finance II, Inc. or Fresenius Medical Care or any present or future member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of FMC Finance VIII S.A. or Fresenius Medical Care US Finance II, Inc. or Fresenius Medical Care or any member of its group. In particular, this release is not an offer to sell or a solicitation of offers to purchase any securities in the United States of America (including its territories and possessions), and securities of FMC Finance VIII S.A. and Fresenius Medical Care US Finance II, Inc. and Fresenius Medical Care may not be offered or sold in the United States of America or to United States persons absent registration under the Securities Act of 1933, as amended, or pursuant to an applicable exemption from registration.

***